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ABSTRACT
OBJECTIVE
To assess the impact of COVID-19 on neurovascular 
research and deal with the challenges imposed by the 
pandemic.
Methods A survey- based study focused on randomized 
controlled trials (RCTs) and single- arm studies for acute 
ischemic stroke and cerebral aneurysms was developed 
by a group of senior neurointerventionalists and sent 
to sites identified through the clinical trials website 
(https:// clinicaltrials. gov/), study sponsors, and physician 
investigators.
Results The survey was sent to 101 institutions, with 
65 responding (64%). Stroke RCTs were being conducted 
at 40 (62%) sites, aneurysm RCTs at 22 (34%) sites, 
stroke single- arm studies at 37 (57%) sites, and 
aneurysm single- arm studies at 43 (66%) sites. Following 
COVID-19, enrollment was suspended at 51 (78%) 
sites—completely at 21 (32%) and partially at 30 (46%) 
sites. Missed trial- related clinics and imaging follow- ups 
and protocol deviations were reported by 27 (42%), 
24 (37%), and 27 (42%) sites, respectively. Negative 
reimbursements were reported at 17 (26%) sites. The 
majority of sites, 49 (75%), had put new trials on hold. 
Of the coordinators, 41 (63%) worked from home and 
20 (31%) reported a personal financial impact. Remote 
consent was possible for some studies at 34 (52%) 
sites and for all studies at 5 (8%) sites. At sites with 
suspended trials (n=51), endovascular treatment without 
enrollment occurred at 31 (61%) sites for stroke and 23 
(45%) sites for aneurysms. A total of 277 patients with 
acute ischemic stroke and 184 with cerebral aneurysms 
were treated without consideration for trial enrollment.
Conclusion Widespread disruption of 
neuroendovascular trials occurred because of COVID-19. 
As sites resume clinical research, steps to mitigate similar 
challenges in the future should be considered.
INTRODUCTION
The neurovascular community has had to date a 
relatively homogeneous response to the COVID-19 
pandemic with regards to clinical care. Measures 
including elective case suspension and modifications 
for emergency treatment and safety procedures to 
accommodate patients with COVID-19 have been 
widely adopted. Societal guidelines containing over-
lapping recommendations, based on evidence in the 
literature and expert consensus, were published to 
codify this.1–3 By contrast, the impact of COVID-19 
on clinical research efforts has been less clear.
The Food and Drug Administration (FDA) 
published its guidance on the 'Conduct Of Clin-
ical Trials Of Medical Products During COVID-19 
Pandemic' for the industry, investigators, and insti-
tutional review boards in March 2020 and updated 
these on April 2, 2020 (https://www. fda. gov/ media/ 
136238/ download). This guidance is expected to 
remain in effect until the public health emergency 
related to the pandemic is lifted by the Department 
of Health and Human Services. The FDA document 
is comprehensive and recognizes the challenges 
due to quarantines, suspension of trials, and inter-
ruption of supply chains. It also recognizes that 
protocol deviations are likely and that trial modi-
fications may be required. Similar guidelines were 
issued by the European Medicines Agency on the 
management of clinical trials during the COVID-19 
pandemic on April 28, 2020 (https:// ec. europa. eu/ 
health/ sites/ health/ files/ files/ eudralex/ vol- 10/ guid 
ance clin ical trials_ covid19_ en. pdf).
Disruption of clinical research infrastructure has 
implications for patient enrollment, study timing, 
sponsorship, and advances in clinical care and 
disease understanding. At the time of writing, fears 
of resurgent or re- emergent disease remain prom-
inent.4 The impetus of this study was clinical trial 
suspension and challenges in patient monitoring 
experienced by several physician investigators and 
enrolling sites. This led to formulation of a hypoth-
esis and study design which aimed to evaluate the 
impact of COVID-19 on neurovascular research 
studies and had a goal of better understanding the 
implications for existing and future trials.
METHODS
Institutional review board approval was not 
obtained as the survey did not involve study of 
human subjects. A survey writing group committee, 
comprising 12 neurointerventional physicians (four 
neuroradiologists, five neurosurgeons, and three 
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neurologists) each with 10 or more years of experience in clinical 
practice, was assembled. All were involved in neurovascular clin-
ical trials as site principal investigators and six were leading clin-
ical trials as national principal investigators. The writing group 
was tasked with composing a concise survey, limited to fewer 
than 20 questions, to be completed by institutional research 
coordinators to explore the effect of COVID-19 on neurointer-
ventional research and clinical trials (full survey can be found in 
online supplementary materials A). The survey focused on endo-
vascular trials for acute ischemic stroke and cerebral aneurysms, 
including both randomized clinical trials (RCTs) and single- arm 
studies. The specific trial names or study sponsors were not 
recorded to protect confidentiality. The site name was only 
logged to assure one response from each site. No compensation 
was offered to participants. No requests to complete the survey 
were placed on public social media platforms. The questions 
were intended to explore key aspects of managing clinical trials 
in a restricted environment as imposed by the pandemic. These 
were identified by the writing group and fell into four catego-
ries: general disruption caused by trial suspensions and missed 
opportunities of enrollment, compromised trial quality due to 
inability of timely clinical and imaging follow- up, inability to 
enroll neurologically debilitated patients because legally autho-
rized representatives were not at hand for face to face consent 
and dated remote consent procedures did not apply and, finally, 
personal effect of compensation or working conditions on study 
staff. The question about remote consent related to existing oper-
ating procedures for ongoing trials. The suspension of clinical 
trials was divided into partial or complete suspension based on 
whether some or all neuroendovascular trials were suspended. 
In cases of partial suspension, the question did not give details 
of the criteria for suspending some trials and not others. The 
survey also did not seek information on the size of the program, 
case volume, or association with a research consortium. This was 
partly to ensure that the brevity of the survey was maintained, 
and partly to maintain broad applicability of the survey regard-
less of program size, academic affiliation, or geographic loca-
tion. The final questionnaire was also reviewed by three industry 
sponsors of clinical trials, two of which agreed to disclose their 
names (Stryker Neurovascular; Fremont, California, USA and 
Cerenovus; Miami, Florida, USA).
The survey sample was identified by creating a list of partic-
ipants from the federal repository website ( clinicaltrials. gov). 
The website allows combinations of search terms to identify 
clinical trials. The search terms used included 'stroke', 'throm-
bectomy', and 'brain aneurysms' with the geographic localizer of 
clinical trials in the 'United States'. The results were filtered for 
recruiting trials. The website provided contact details for each 
study. In a separate process, various study sponsors and prin-
cipal investigators of ongoing clinical trials were approached 
by members of the writing group and asked to provide lists of 
participating sites. The accumulated sites were cross referenced 
with the list generated from  clinicaltrials. gov to eliminate dupli-
cates and when site information was missing, physician investi-
gators localized by state were identified and invited individually 
through the Society of Neurointerventional Surgery senior 
physician membership (https://www. snisonline. org/). The final 
sample resulted in a total of 101 institutions identified for 
potential participation.
The finalized survey was prepared on Qualtrics (https://www. 
qualtrics. com) using an institutional license. The survey was 
distributed to the identified sites by email and was open for a 
4- week period from April 21, 2020 to May 21, 2020. To boost the 
response rate, a digital link to the survey and a printable version 
(PDF, Word document) were emailed to the physician investiga-
tors and study coordinators midway through the 4- week period 
as a prompt. Surveys were completed voluntarily by a research 
coordinator at each institution with the help of the physician 
investigator as required. Each center was permitted only one 
response. The survey is presented as descriptive statistics.
RESULTS
The survey was sent to study coordinators at 101 institutions 
with 65 responding (64%). All responding sites were actively 
involved in neurovascular trials before the COVID-19 pandemic. 
Of the returned forms, the only missing responses related to 
entry of the date of clinical trial suspension (if applicable). An 
evaluation of endovascular studies showed that a majority of 
sites were conducting stroke- related RCTs or single- arm studies. 
Most sites were also conducting single- arm aneurysm trials 
while a minority were participating in aneurysm- related RCTs 
(figure 1A).
During the pandemic, the majority of the sites either partially 
or completely suspended enrollment in clinical trials (figure 1B), 
with the suspension occurring between the middle to the end of 
March 2020. There was no correlation between site trial suspen-
sion and geographic location or academic affiliation. Suspen-
sion of sites by state showed a heterogeneity of response, with 
different sites in same state having different responses (figure 2). 
No correlation was found between trial suspension and the 
intensity of the pandemic.
Figure 1 (A) The randomized controlled trials (RCTs) and single arm studies for stroke and aneurysms being conducted at the responding sites 
(n=65) prior to COVID-19. (B) clinical trial suspension at the responding sites during the pandemic.
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Endovascular stroke care continued in sites where enrollment 
had been suspended (n=51), and most of these sites treated 
patients with acute ischemic stroke without enrollment. Almost 
half of the sites treated patients with an aneurysm (figure 3A). 
A total of 277 patients with endovascular stroke and 184 with 
endovascular aneurysm were treated without consideration for 
enrollment following suspension of clinical trials. Effects were 
also observed on patients already enrolled in trials. Forty- two 
percent of sites missed clinical follow- up visits, and 37% missed 
imaging follow- up. Under half of the sites (42%) reported 
protocol deviations because of the pandemic and a quarter 
reported loss of reimbursements possibly due to delayed or 
missed milestones or inability to enroll patients (figure 3B). 
Almost all (61/65, 94%) sites had developed alternative mecha-
nisms such as telemedicine for clinical visits.
Most of the sites had received institutional review board guid-
ance for the conduct of clinical trials (n=57, 88%) and most had 
received guidance from sponsors for either all (n=31, 48%) or 
some (n=30, 46%) of the clinical trials. Over half of the sites 
allowed electronic or phone consent for enrollment (figure 4). 
There were widespread challenges for study staff, with the 
majority of the study coordinators working from home (n=41, 
63%) or a combination of home and office (n=18, 28%) and 
almost a third (n=20, 31%) reporting being personally affected 
by the pandemic either due to loss of pay, paid time off, or loss 
of benefits. The majority of the sites (n=49, 75%) had placed 
new trials on hold, with the number of postponed trials per site 
ranging from one to seven. Two sites reported a diagnosis of 
COVID-19 among the enrolled patients.
DISCUSSION
This study identified widespread disruptions to neurovascular 
clinical trial networks, most notably due to a suspension or post-
ponement of trial enrollment, interruptions in scheduled patient 
follow- up, and challenges with study staff routines. Cessation 
of ongoing trials was nearly uniform, which may have down-
stream effects on trial validity and solvency. Understanding the 
effect of COVID-19 on clinical trials during the early months 
of the pandemic is especially important given the uncertainty 
about the future and potential need for subsequent lockdowns 
should widespread infection recur after resumption of elective 
procedures and relaxation of social distancing measures. One 
previous letter has been published, documenting decreased 
enrollment related to the pandemic in cancer- related clinical 
trials,5 and another systematic review on cancer research during 
COVID-19.6 The Federation of Italian Cooperative Oncology 
group issued a brief commentary and practice indications for 
drug studies.7 Other publications have included clinical trials 
for Alzheimer’s research,8 and a review for guidance in head 
and neck research.9 At the time of writing, no published studies 
measuring the comprehensive impact of COVID-19 on research 
are available, and while this study focuses specifically on neuro-
vascular research and trials, disruptions captured may well be 
generalizable to United States clinical trials in other medical 
specialties.
A prominent source of disruption identified by this survey was 
the complete or partial suspension of trial enrollment. Many 
sites with suspended enrollment treated potentially eligible 
Figure 2 A chart of trial suspensions by state. The width of the bar for a given state correlates to the number of sites responding from that state. 
The wider the bar, the more the sites responding from that state. These are depicted in ascending order from left to right.
Figure 3 (A) Sites with partial or complete suspension (n=51) reporting endovascular treatment of patients with stroke or an aneurysm without 
enrollment. (B) Sites reporting missed clinical or imaging follow- up visits, protocol deviations, and loss of reimbursements. AIS, acute ischemic stroke.
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patients with stroke and aneurysm. A total of 277 patients with 
stroke and 184 with an aneurysm reportedly underwent endo-
vascular therapy at these sites during the period in which the 
survey was conducted and thus could not be considered for 
enrollment owing to the suspension of clinical research. In view 
of the number of sites that did not respond to the survey, this 
number may be even higher. Unlike the 'clinical deficit', which 
is expected to be gradually overcome by returning case volume 
and case rescheduling, no similar option exists for research 
enrollment deficits. The most likely means of compensating for 
missed enrollments is to extend trial enrollment timelines. Such 
extension has implications for funding, compounded by poten-
tial contraction of funding following the wider economic impact 
of the global pandemic.
Beyond enrollment alone, trial quality was compromised. 
Many patients missed clinical and imaging follow- up mile-
stones, and many sites reported protocol deviations due to the 
pandemic. These may increase as pandemic effects continue and 
could affect the veracity of overall trial data. Site trial infra-
structure will have to adjust to new realities of reduced funding 
for many centers, with just over a quarter reporting a negative 
impact on reimbursements.
Human trial expertise has also been affected by the COVID-19 
pandemic. Sites could experience reassignment, furloughing, or 
termination of study coordinators. One- third of responding 
coordinators reported a direct personal effect through loss of 
pay, time off, or benefits. As operations gradually return, this 
human expertise may need to be rebuilt. Trialists and staff will 
also need ongoing protection from potential infectious expo-
sures.10 Failure to do so could affect a site’s ability to perform 
existing and future trials unless alternative mechanisms are 
developed.
As clinical research activities resume with lifting of mandated 
lockdowns, this survey highlights several opportunities to update 
the conduct of clinical trials in accordance with the virtual care 
revolution brought about by the COVID-19 pandemic.11 12 
In this survey, 40% of the responding sites did not have any 
protocols in place for remote consent. Challenges to the tradi-
tional consent process could persist into the foreseeable future 
as hospital visitor restrictions are likely to remain in place for 
some time. Study sponsors, local institutional review boards, and 
federal authorities regulating these trials will have to demon-
strate creativity in modernizing these procedures. Harnessing 
emerging virtual technologies that allow for face- to- face interac-
tions with legally authorized representatives, electronic exchange 
of documents, and digital signatures, represents a clear opportu-
nity. It is possible to comply with the ethical principles governing 
informed consent while updating these procedures to meet the 
current and future needs of operating with restricted visits.13
In the recovery phase there are calls in both public and 
medical circles for our healthcare infrastructure to focus on 
broadly improving our approaches, not simply returning to 
the prior state of normalcy.14 For acute trials in particular this 
could have broad positive implications for enrollment. Further, 
there are opportunities to enhance virtual capabilities to conduct 
trials, with reduced reliance on in- person monitoring and 
reporting forms. Based on existing data about telehealth,15 this 
may expand the trial footprint, decrease trial costs, and poten-
tially increase trial efficiency. Trial reorganization into adaptive 
designs like platform trials may allow us to respond more rapidly 
to design changes and randomize more effectively as new ques-
tions arise.16 Early efforts are underway to develop a neurovas-
cular platform trial infrastructure, and this should remain a focus 
for the neurointerventional community.
Another important consideration is how to handle potential 
trial candidates regarding COVID-19 exposure. In this survey, 
a small number (two sites) reported a positive COVID-19 diag-
nosis in enrolled patients. There is current uncertainty about how 
to process patients with COVID-19 in neurovascular trials or 
whether to screen based on symptoms or exposures. The direct 
effect of SARS- CoV-2 on cerebrovascular disease remains largely 
unknown, but early evidence suggests endothelial involvement17 
and a range of syndromes18–20 that could confound the natural 
history of the disease or treatment response. This may be partic-
ularly relevant for studies of cerebrovascular conditions where 
patient outcomes may be directly influenced apart from the inter-
ventions being studied. How patients with COVID-19 should be 
handled by trials that are not focused on that disease specifically, 
is unknown. Testing all potential enrollees for COVID-19 and 
excluding all positive patients a priori seems reasonable, but this 
could result in unnecessary delays in enrollment or exclusion of 
patients who are COVID false positive or who have recovered 
from COVID. This larger question will probably be answered 
as we learn more about the virus. As more data are collected on 
the impact of the pandemic on clinical trials it may be possible 
to crystallize strategies for operating in a restrictive environment 
due to lingering concerns of outbreaks.
Limitations
This study has several important limitations. As a survey study, 
this study is subject to the inherent limitations of survey meth-
odology, including recall and selection bias. The potential for 
selection bias is strong as those most affected by the pandemic 
may be more likely to complete the surveys. Additionally, centers 
with furloughed or terminated coordinators were unable to 
provide responses. A number of potentially important research 
or practice- specific questions, such as region or the prevalence of 
COVID-19 in the population, were not included in the survey by 
the writing group to improve participation rates. Questions were 
intentionally generated to assess a broad overview of research 
Figure 4 Remote consent policies adopted at responding sites.
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as opposed to specifically focus on individual trial statistics. 
The survey questions were purposely kept under 20, and there-
fore details that might have been helpful in further exploring 
some responses were not obtained. For example, the criteria 
for choosing to keep some trials open and others suspended 
are not known. Likewise, details of the causes of loss of trial- 
related reimbursements were not obtained. Additionally, impli-
cations for neurovascular basic or laboratory- based research, or 
for research in other domains, were similarly not assessed. The 
questions used were not previously validated and were designed 
specifically for the NI research coordinators involved in clinical 
trials, which may limit their generalizability to other specialties 
and make comparison with data from other surveys challenging. 
Lastly, since this type of pandemic has never occurred in modern 
history, there is no previously developed, validated survey instru-
ment to study the effects of a global pandemic on research.
CONCLUSION
This is the first study comprehensively evaluating the effect of 
COVID-19 on clinical trials. Respondents indicated widespread 
disruption of neurovascular clinical research and research infra-
structure during the COVID-19 pandemic. It has also revealed 
opportunities for increased infrastructural strength and pliability, 
including the increased use of virtual access for consent and 
follow- up, and the benefits of platform trial design at times 
when flexibility and responsiveness are key advantages. Many 
questions remain to be answered, including how we should 
incorporate COVID-19 screening into trial criteria. It should be 
expected that disruptions due to COVID-19 will continue, based 
on expert predictions of the disease course. Trial conduct in this 
restrictive environment will need to evolve. Decisions about how 
to maintain enrollment during the current pandemic and in the 
event of future similar disruptions21 must be prioritized.
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